Delving into the Latest Updates on Anhui Willman Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Immune System Diseases

Respiratory Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

GR(Glucocorticoid receptor)	1

In order to ensure the quality of aerosol after the propellant excipients were replaced, post-market clinical trials were conducted according to CFDA requirements, and the clinical safety and efficacy of ciclesonide aerosol (MDI) for the treatment of bronchial asthma developed by Anhui Wellman Pharmaceutical Co., Ltd. after the propellant was replaced were objectively evaluated.

Start Date08 May 2017

Sponsor / Collaborator

Anhui Willman Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with Anhui Willman Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Anhui Willman Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Anhui Willman Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Anhui Willman Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data